Preoperative staging of non-small-cell lung cancer: comparison of whole-body diffusion-weighted magnetic resonance imaging and 18F-fluorodeoxyglucose-positron emission tomography/computed tomography

详细信息    查看全文

• 作者：Gregor Sommer (1)
  Mark Wiese (2)
  Leopold Winter (1)
  Claudia Lenz (3)
  Markus Klarh?fer (3) (4)
  Flavio Forrer (1)
  Didier Lardinois (2)
  Jens Bremerich (1)
  
• 关键词：Non ; small ; cell lung carcinoma ; Neoplasm staging ; Whole ; body imaging ; Diffusion magnetic resonance imaging ; Positron emission tomography
• 刊名：European Radiology
• 出版年：2012
• 出版时间：December 2012
• 年：2012
• 卷：22
• 期：12
• 页码：2859-2867
• 全文大小：362KB
• 参考文献：1. Siegel R, Ward E, Brawley O, Jemal A (2011) Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61:212-36 CrossRef
  2. Toloza EM, Harpole L, McCrory DC (2003) Noninvasive staging of non-small cell lung cancer: a review of the current evidence. Chest 123:137S-46S CrossRef
  3. Lardinois D, Weder W, Hany TF et al (2003) Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 348:2500-507 CrossRef
  4. Aquino SL, Kuester LB, Muse VV, Halpern EF, Fischman AJ (2006) Accuracy of transmission CT and FDG-PET in the detection of small pulmonary nodules with integrated PET/CT. Eur J Nucl Med Mol Imaging 33:692-96 CrossRef
  5. Roberts PF, Follette DM, von Haag D et al (2000) Factors associated with false-positive staging of lung cancer by positron emission tomography. Ann Thorac Surg 70:1154-160 CrossRef
  6. Takahara T, Imai Y, Yamashita T, Yasuda S, Nasu S, Van Cauteren M (2004) Diffusion weighted whole body imaging with background body signal suppression (DWIBS): technical improvement using free breathing, STIR and high resolution 3D display. Radiat Med 22:275-82
  7. Matsumoto Y, Kuroda M, Matsuya R et al (2009) In vitro experimental study of the relationship between the apparent diffusion coefficient and changes in cellularity and cell morphology. Oncol Rep 22:641-48
  8. Kwee TC, Takahara T, Ochiai R, Nievelstein RAJ, Luijten PR (2008) Diffusion-weighted whole-body imaging with background body signal suppression (DWIBS): features and potential applications in oncology. Eur Radiol 18:1937-952 CrossRef
  9. Mori T, Nomori H, Ikeda K et al (2008) Diffusion-weighted magnetic resonance imaging for diagnosing malignant pulmonary nodules/masses: comparison with positron emission tomography. J Thorac Oncol 3:358-64 CrossRef
  10. Ohba Y, Nomori H, Mori T et al (2009) Is diffusion-weighted magnetic resonance imaging superior to positron emission tomography with fludeoxyglucose F 18 in imaging non-small cell lung cancer? J Thorac Cardiovasc Surg 138:439-45 CrossRef
  11. Usuda K, Zhao XT, Sagawa M et al (2011) Diffusion-weighted imaging is superior to positron emission tomography in the detection and nodal assessment of lung cancers. Ann Thorac Surg 91:1689-695 CrossRef
  12. Chen W, Jian W, H-tao L et al (2010) Whole-body diffusion-weighted imaging vs. FDG-PET for the detection of non-small-cell lung cancer. How do they measure up? Magn Reson Imaging 28:613-20 CrossRef
  13. Nomori H, Mori T, Ikeda K et al (2008) Diffusion-weighted magnetic resonance imaging can be used in place of positron emission tomography for N staging of non-small cell lung cancer with fewer false-positive results. J Thorac Cardiovasc Surg 135:816-22 CrossRef
  14. Ohno Y, Koyama H, Yoshikawa T et al (2011) N stage disease in patients with non-small cell lung cancer: efficacy of quantitative and qualitative assessment with STIR turbo spin-echo imaging, diffusion-weighted MR imaging, and fluorodeoxyglucose PET/CT. Radiology 261:605-15 CrossRef
  15. Ohno Y, Koyama H, Onishi Y et al (2008) Non-small cell lung cancer: whole-body MR examination for M-stage assessment—utility for whole-body diffusion-weighted imaging compared with integrated FDG PET/CT. Radiology 248:643-54 CrossRef
  16. Satoh S, Kitazume Y, Ohdama S, Kimula Y, Taura S, Endo Y (2008) Can malignant and benign pulmonary nodules be differentiated with diffusion-weighted MRI? AJR Am J Roentgenol 191:464-70 CrossRef
  17. Uto T, Takehara Y, Nakamura Y et al (2009) Higher sensitivity and specificity for diffusion-weighted imaging of malignant lung lesions without apparent diffusion coefficient quantification. Radiology 252:247-54 CrossRef
  18. Takenaka D, Ohno Y, Matsumoto K et al (2009) Detection of bone metastases in non-small cell lung cancer patients: comparison of whole-body diffusion-weighted imaging (DWI), whole-body MR imaging without and with DWI, whole-body FDG-PET/CT, and bone scintigraphy. J Magn Reson Imaging 30:298-08 CrossRef
  19. Nakayama J, Miyasaka K, Omatsu T et al (2010) Metastases in mediastinal and hilar lymph nodes in patients with non-small cell lung cancer: quantitative assessment with diffusion-weighted magnetic resonance imaging and apparent diffusion coefficient. J Comput Assist Tomogr 34:1- CrossRef
  20. Liu H, Liu Y, Yu T, Ye N (2012) Usefulness of diffusion-weighted MR imaging in the evaluation of pulmonary lesions. Eur Radiol 20:807-15 CrossRef
  21. Pauls S, Schmidt SA, Juchems MS et al (2010) Diffusion-weighted MR imaging in comparison to integrated [(18)F]-FDG PET/CT for N-staging in patients with lung cancer. Eur J Radiol 81:178-82 CrossRef
  22. Hasegawa I, Boiselle PM, Kuwabara K, Sawafuji M, Sugiura H (2008) Mediastinal lymph nodes in patients with non-small cell lung cancer: preliminary experience with diffusion-weighted MR imaging. J Thorac Imaging 23:157-61 CrossRef
  23. Matoba M, Tonami H, Kondou T et al (2007) Lung carcinoma: diffusion-weighted MR imaging—preliminary evaluation with apparent diffusion coefficient. Radiology 243:570-77 CrossRef
  24. Ko?ucu P, Tekinba? C, Erol M et al (2009) Mediastinal lymph nodes: assessment with diffusion-weighted MR imaging. J Magn Reson Imaging 30:292-97 CrossRef
  25. Travis WD, Colby TV, Corrin B et al (1999) Histological typing of lung and pleural tumours, 3rd edn. Springer, Berlin Heidelberg CrossRef
  26. UyBico SJ, Wu CC, Suh RD, Le NH, Brown K, Krishnam MS (2010) Lung cancer staging essentials: the new TNM staging system and potential imaging pitfalls. Radiographics 30:1163-181 CrossRef
  27. Rusch VW, Asamura H, Watanabe H et al (2009) The IASLC lung cancer staging project: a proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol 4:568-77 CrossRef
  28. Subedi N, Scarsbrook A, Darby M, Korde K, Mc Shane P, Muers MF (2009) The clinical impact of integrated FDG PET-CT on management decisions in patients with lung cancer. Lung Cancer 64:301-07 CrossRef
  29. Muehling B, Wehrmann C, Oberhuber A, Schelzig H, Barth T, Orend KH (2012) Comparison of Clinical and Surgical-Pathological Staging in IIIA Non-Small Cell Lung Cancer Patients. Ann Surg Oncol 19:89-3 CrossRef
  30. Billé A, Pelosi E, Skanjeti A et al (2009) Preoperative intrathoracic lymph node staging in patients with non-small-cell lung cancer: accuracy of integrated positron emission tomography and computed tomography. Eur J Cardiothorac Surg 36:440-45 CrossRef
  31. Li X, Zhang H, Xing L et al (2011) Mediastinal lymph nodes staging by (18)F-FDG PET/CT for early stage non-small cell lung cancer: A multicenter study. Radiother Oncol 102:246-50 CrossRef
  
• 作者单位：Gregor Sommer (1)
  Mark Wiese (2)
  Leopold Winter (1)
  Claudia Lenz (3)
  Markus Klarh?fer (3) (4)
  Flavio Forrer (1)
  Didier Lardinois (2)
  Jens Bremerich (1)
  
  1. Clinic of Radiology and Nuclear Medicine, University of Basel Hospital, Petersgraben 4, 4031, Basel, Switzerland
  2. Clinic of Thoracic Surgery, University of Basel Hospital, Spitalstrasse 21, 4031, Basel, Switzerland
  3. Division of Radiological Physics, Clinic of Radiology and Nuclear Medicine, University of Basel Hospital, Petersgraben 4, 4031, Basel, Switzerland
  4. Siemens Switzerland Ltd., Healthcare Sector, Zurich, Switzerland
  
• ISSN：1432-1084

文摘

Objective To investigate the diagnostic value of whole-body magnetic resonance imaging (MRI) including diffusion-weighted imaging with background signal suppression (DWIBS) for preoperative assessment of non-small-cell lung cancer (NSCLC) in comparison to 18F-fluorodeoxyglucose 18FDG) positron emission tomography/computed tomography (PET/CT). Methods Thirty-three patients with suspected NSCLC were enrolled. Patients were examined before surgery with PET/CT and whole-body MRI including T1-weighted turbo spin echo (TSE), T2-weighted short tau inversion recovery (STIR) and DWIBS sequences (b--/800). Histological or cytological specimens were taken as standard of reference. Results Whole-body MRI with DWIBS as well as PET/CT provided diagnostic image quality in all cases. Sensitivity for primary tumour detection: MRI 93%, PET/CT 98%. T-staging accuracy: MRI 63%, PET/CT 56%. N-staging accuracy: MRI 66%, PET/CT 71%. UICC staging accuracy: MRI 66%, PET/CT 74%. Sensitivity for metastatic involvement of individual lymph node groups: MRI 44%, PET/CT 47%. Specificity for individual non-metastatic lymph node groups: MRI 93%, PET/CT 96%. Assessment accuracy for individual lymph node groups: MRI 85%, PET/CT 88%. Observer agreement rate for UICC staging: MRI 74%, PET/CT 90%. Conclusion Whole-body MRI with DWIBS provides comparable results to PET/CT in staging of NSCLC, but shows no superiority. Most relevant challenges for both techniques are T-staging accuracy and sensitivity for metastatic lymph node involvement. Key Points -Numerous radiological methods are available for the crucial staging of lung cancer -Whole-body DWIBS MRI provides comparable results to PET/CT in NSCLC staging. -No evident superiority of whole-body DWIBS over PET/CT in NSCLC staging. -Challenges for both techniques are T-staging and detection of small metastases.